GLP-1 weight‑loss drugs reshape U.S. health policy and consumer markets

A Gallup survey released July 7 2026 found that about 40 million U.S. adults—roughly 11 % of the adult population—are now using GLP‑1 medications for weight loss, a four‑fold increase from 2024. Beginning July 1 2026 Medicare Part D beneficiaries can obtain approved GLP‑1 drugs such as Wegovy, Zepbound and Foundayo for a flat $50 monthly copay under the new Medicare GLP‑1 Bridge, a move the CMS administrator described as ending “the cost barrier” that kept many seniors from treatment. The coverage change coincides with a modest drop in the national obesity rate, from a 2022 peak of 39.9 % to 36.4 % in 2026.

At the same time, safety concerns have risen. Poison‑center calls about injectable GLP‑1 overdoses surged by nearly 1,500 % between 2019 and 2025, totaling almost 23,000 reports. A 54‑year‑old North Carolina woman, Leslie Gammon, was hospitalized after a telehealth‑prescribed dosage increase caused severe vomiting; she recalled, “I just kept throwing up, it felt like every 20 minutes.” Experts warn that remote prescribing may lack the clinical safeguards of in‑person care.

Retail and food producers are already adjusting. EnsembleIQ announced a GLP‑1 Shopper Summit to examine how the drugs are reshaping grocery baskets, with research forecasting that 23 % of U.S. households now, and potentially 35 % by 2030, will base food purchases on GLP‑1 use. In Australia, analysts see new marketing opportunities for red meat and protein‑rich products as older consumers on GLP‑1 seek nutrient‑dense foods, while EY‑Parthenon models predict reduced spending on sugary snacks, alcohol and processed foods and increased demand for fresh and protein‑focused items.